Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Springfield Properties lifts profit outlook after solid H1

(Sharecast News) - Scottish housebuilder Springfield Properties said it expects full-year profits to be "significantly ahead of market expectations" after a strong improvement in margins drove impressive earnings growth in the first half. Adjusted profit before tax in the six months ended 30 November totalled £3.8m, up 90% year-on-year, helped by a 300-basis point improvement in the gross margin to 17.7%, as well as a "sustained focus on cost control and land sales", the company said.

Total revenues were down 13% at £105.6m, with completions falling to 361 from 432 the year before.

Springfield said that the start certain affordable housing contracts was delayed during the period due to uncertainty around availability of Scottish government funding, but activity has increased since period-end following the Scottish Budget in December.

The company also said on Monday that it had entered an agreement with a Barratt Redrow subsidiary for the sale of 2,480 plots of undeveloped land for £64.2m in cash, which will be received over four years and used to "accelerate the removal of the Group's bank debt and to capitalise on the significant opportunities in the North of Scotland".

In addition, Springfield is in talks regarding the sale of further future land holdings on a number of sites to Barratt Redrow.

Net bank debt stood at £62.9m by the end of the half, down from £93.4m at the start of the period.

Shares were up 10.4% at 108.75p by 1008 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.